Archives

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Using the National Drug Discovery Centre, researchers from the Walter and Eliza Hall Institute identified drug-like compounds that could block a key coronavirus protein called PLpro. This protein, found in all coronaviruses, is essential for the virus to hijack and multiply within human cells, and disable their anti-viral defences.

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our understanding of the virus to help develop treatments and vaccines quicker. A new website that allows scientists to share difficult-to-find SARS-CoV-2 data from clinical trials, research centres, hospitals and national healthcare systems, has seen thousands of users collaborating to help beat the novel coronavirus.

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.(1) The trial will include up to 48 healthy participants in the UK aged 18 to 55 years and is funded by the